NASDAQ:AKER

Akers Biosciences Stock Forecast, Price & News

$3.21
-0.11 (-3.31 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.20
Now: $3.21
$3.36
50-Day Range
$2.64
MA: $3.31
$3.93
52-Week Range
$1.65
Now: $3.21
$6.97
Volume52,080 shs
Average Volume775,710 shs
Market Capitalization$53.46 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
There is no company description available for Akers Biosciences Inc.
Akers Biosciences logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKER
CUSIPN/A
PhoneN/A
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.58 million
Book Value$5.38 per share

Profitability

Net Income$-3,890,000.00

Miscellaneous

Market Cap$53.46 million
Next Earnings Date5/21/2021 (Estimated)
OptionableNot Optionable

Headlines

RM LAW Announces Investigation of Akers Biosciences, Inc.
November 17, 2020 |  finance.yahoo.com
Akers Biosciences' stock soars 29% on merger deal
November 13, 2020 |  bizjournals.com
Why Akers Biosciences Stock Is Trading Higher Today
November 12, 2020 |  benzinga.com
See More Headlines

MarketRank

Overall MarketRank

0.71 out of 5 stars

Medical Sector

1260th out of 2,010 stocks

Diagnostic Substances Industry

22nd out of 32 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$3.21
-0.11 (-3.31 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What stocks does MarketBeat like better than Akers Biosciences?

Wall Street analysts have given Akers Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akers Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Akers Biosciences?

Akers Biosciences saw a increase in short interest in February. As of February 26th, there was short interest totaling 1,670,000 shares, an increase of 65.3% from the February 11th total of 1,010,000 shares. Based on an average daily trading volume, of 828,300 shares, the short-interest ratio is currently 2.0 days. Currently, 18.9% of the company's stock are sold short.
View Akers Biosciences' Short Interest
.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Akers Biosciences
.

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) announced its quarterly earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.
View Akers Biosciences' earnings history
.

How has Akers Biosciences' stock been impacted by Coronavirus (COVID-19)?

Akers Biosciences' stock was trading at $2.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AKER shares have increased by 42.0% and is now trading at $3.21.
View which stocks have been most impacted by COVID-19
.

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the following people:
  • Mr. Christopher C. Schreiber, CEO, Principal Exec. Officer, Pres & Director (Age 56, Pay $507.62k)
  • Mr. Ian Rhodes, Interim Chief Financial Officer (Age 48)
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 65)

What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO?

3 employees have rated Akers Biosciences CEO Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among Akers Biosciences' employees.

Who are some of Akers Biosciences' key competitors?

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu Biopharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $3.21.

How much money does Akers Biosciences make?

Akers Biosciences has a market capitalization of $53.46 million and generates $1.58 million in revenue each year.

How many employees does Akers Biosciences have?

Akers Biosciences employs 12 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

Where are Akers Biosciences' headquarters?

Akers Biosciences is headquartered at 201 GROVE RD, THOROFARE NJ, 08086.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via email at [email protected]


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.